HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

AbstractBACKGROUND:
Idiopathic membranous nephropathy is an autoimmune disease. In approximately 70% of patients, it is associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1). Antigenic targets in the remaining patients are unknown.
METHODS:
Using Western blotting, we screened serum samples from patients with idiopathic membranous nephropathy, patients with other glomerular diseases, and healthy controls for antibodies against human native glomerular proteins. We partially purified a putative new antigen, identified this protein by means of mass spectrometry of digested peptides, and validated the results by analysis of recombinant protein expression, immunoprecipitation, and immunohistochemical analysis.
RESULTS:
Serum samples from 6 of 44 patients in a European cohort and 9 of 110 patients in a Boston cohort with anti-PLA2R1-negative idiopathic membranous nephropathy recognized a glomerular protein that was 250 kD in size. None of the serum samples from the 74 patients with idiopathic membranous nephropathy who were seropositive for anti-PLA2R1 antibodies, from the 76 patients with other glomerular diseases, and from the 44 healthy controls reacted against this antigen. Although this newly identified antigen is clearly different from PLA2R1, it shares some biochemical features, such as N-glycosylation, membranous location, and reactivity with serum only under nonreducing conditions. Mass spectrometry identified this antigen as thrombospondin type-1 domain-containing 7A (THSD7A). All reactive serum samples recognized recombinant THSD7A and immunoprecipitated THSD7A from glomerular lysates. Moreover, immunohistochemical analyses of biopsy samples from patients revealed localization of THSD7A to podocytes, and IgG eluted from one of these samples was specific for THSD7A.
CONCLUSIONS:
In our cohort, 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to THSD7A but not to PLA2R1, a finding that suggests a distinct subgroup of patients with this condition. (Funded by the French National Center for Scientific Research and others.).
AuthorsNicola M Tomas, Laurence H Beck Jr, Catherine Meyer-Schwesinger, Barbara Seitz-Polski, Hong Ma, Gunther Zahner, Guillaume Dolla, Elion Hoxha, Udo Helmchen, Anne-Sophie Dabert-Gay, Delphine Debayle, Michael Merchant, Jon Klein, David J Salant, Rolf A K Stahl, Gérard Lambeau
JournalThe New England journal of medicine (N Engl J Med) Vol. 371 Issue 24 Pg. 2277-2287 (Dec 11 2014) ISSN: 1533-4406 [Electronic] United States
PMID25394321 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantibodies
  • PLA2R1 protein, human
  • Receptors, Phospholipase A2
  • THSD7A protein, human
  • Thrombospondins
Topics
  • Autoantibodies (blood)
  • Blotting, Western
  • Case-Control Studies
  • Glomerulonephritis, Membranous (blood, immunology)
  • Humans
  • Kidney Glomerulus (metabolism)
  • Receptors, Phospholipase A2 (blood, immunology, metabolism)
  • Thrombospondins (blood, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: